Andreas Roller

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications

Reply to: Prior BRAF Inhibitor Exposure Is Not Enough to Define Resistance in the Phase I Mosperafenib Study.

Reply to: Prior BRAF Inhibitor Exposure Is Not Enough to Define Resistance in the Phase I Mosperafenib Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 27, 2026

Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600-Mutant Solid Tumors.

Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600-Mutant Solid Tumors.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 27, 2026

Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer.

Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer.

Journal: Cancer research communications
Published: March 10, 2026

Biomarkers of activity from a phase I study of cergutuzumab amunaleukin in patients with advanced solid tumors.

Biomarkers of activity from a phase I study of cergutuzumab amunaleukin in patients with advanced solid tumors.

Journal: Journal for immunotherapy of cancer
Published: December 01, 2025

Translational strategy to support the first-in-human study of a TCR-like T cell bispecific with an in vitro-based safety approach.

Translational strategy to support the first-in-human study of a TCR-like T cell bispecific with an in vitro-based safety approach.

Journal: Frontiers in immunology
Published: October 31, 2025

Identification of conserved immune-related adverse event risk factors and clinical outcomes in a pan-immunotherapy data mart.

Identification of conserved immune-related adverse event risk factors and clinical outcomes in a pan-immunotherapy data mart.

Journal: Journal for immunotherapy of cancer
Published: October 22, 2025

First-in-human study of an EGFRvIII x CD3 T cell bispecific antibody in the treatment of newly diagnosed glioblastoma.

First-in-human study of an EGFRvIII x CD3 T cell bispecific antibody in the treatment of newly diagnosed glioblastoma.

Journal: Neuro-oncology advances
Published: August 22, 2025

Mapping MAGE-A4 expression in solid cancers for targeted therapies.

Mapping MAGE-A4 expression in solid cancers for targeted therapies.

Journal: Frontiers in oncology
Published: August 21, 2024

Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+T cells in the tumor microenvironment and predicts clinical outcome in early-phase and late-phase clinical trials.

Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+T cells in the tumor microenvironment and predicts clinical outcome in early-phase and late-phase clinical trials.

Journal: Journal for immunotherapy of cancer
Published: March 18, 2024

Matching by OS Prognostic Score to Construct External Controls in Lung Cancer Clinical Trials.

Matching by OS Prognostic Score to Construct External Controls in Lung Cancer Clinical Trials.

Journal: Clinical pharmacology and therapeutics
Published: August 09, 2023

Circulating tumor DNA: Opportunities and challenges for pharmacometric approaches.

Circulating tumor DNA: Opportunities and challenges for pharmacometric approaches.

Journal: Frontiers in pharmacology
Published: September 30, 2022

Corrigendum: Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity.

Corrigendum: Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity.

Journal: Frontiers in oncology
Published: January 06, 2021
Showing 1-12 of 18

Last Updated: 09/26/2026